Wire · opportunities
BMS halt tests Orum valuation as Korea biotech pivots to new DAC trials
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 September 2026 · Fusion42 review
Bristol Myers Squibb (BMS) has halted development of Orum Therapeutics' acute myeloid leukemia drug candidate ORM-6151 and terminated their asset transfer agreement. This setback challenges the clinical validation of Orum's GSPT1-based antibody-degrader conjugate (DAC) technology, putting pressure on its valuation and future technology transfer prospects.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 18 Sep 2026 and 20 Sep 2026.
◆ ◆ The Wire takeaway
You face a validation crisis for GSPT1 degrader therapies as big pharma pulls support. Secure clinical proof for your next DAC pipeline quickly or risk permanent loss of industry trust.
◆ Coverage
2 sources · first reported 18 Sep 2026 · latest 20 Sep 2026
◆ Related on Wire
◆ Topics